About Entering Phase 3 RRx-001

A new class of anti-cancer therapy with the potential to convert “treatment-resistant” tumors into “treatment sensitive” tumors

First-generation therapies, which target “checkpoint inhibitors”, have revolutionized the treatment of cancer, but only a small set of patients derives benefit. One of the reasons that not all patients respond to treatment is the presence of myeloid-derived suppressor cells in the tumor microenvironment.

Multimechanistic RRx-001 is a first-in-class small molecule immunotherapeutic that targets the CD47 – SIRPα axis and repolarizes tumor associated macrophages (TAMs) and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype.

RRx-001 can be used as monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy as an anti-cancer therapy, which also protects normal tissues.

RRx-001 was recently granted orphan drug designation for SCLC and neuroendocrine cancer in the US by the FDA and for SCLC in Europe by the EMA.

EpicentRx is currently sponsoring a Phase 3 clinical trial called REPLATINUM for patients with advanced small cell carcinoma, investigating the activity and safety of RRx-001 in combination with platinum doublet chemotherapy versus platinum chemotherapy alone. The REPLATINUM study will commence enrollment in late 2018.

For a full list of currently enrolling clinical trials featuring RRx-001 please visit our Clinical Trials page.

For further information about RRx-001 mechanism of action and research please refer to our publications page.

For general inquiries about RRx-001, please contact us at info@epicentrx.com.